Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?



Rating:

Share or cite this content

Citations should be made in the following way:
T. Welte (Hanover, Germany). Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia?. Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?

Member's Comments

No comment yet.

Related content which might interest you: COPD is associated with increased mortality in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: 346-351 Year: 2006 COPD: what is the frequency and impact of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 106s Year: 2006 Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Source: Eur Respir J 2006; 28: 262-263 Year: 2006 Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients Source: Eur Respir J 2012; 39: 855-861 Year: 2012 is hypercapnia associated with severe forms of community-acquired pneumonia? Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Budesonide is not associated with increased risk of pneumonia in COPD patients Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Obesity is associated with improved outcome in community-acquired pneumonia Source: Annual Congress 2012 - Prognosis and outcome of respiratory infections Year: 2012 Factors associated with unknown aetiology in patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: 1254-1262 Year: 2002 The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Factors associated with unknown aetiology in patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 560s Year: 2002 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 How can I differentiate community-acquired pneumonia (CAP)+COPD patients from acute exacerbation of COPD (AECOPD) patients? Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients Year: 2015 Obesity is associated with improved survival in community-acquired pneumonia Source: Eur Respir J 2013; 42: 180-187 Year: 2013 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010